
Alectinib 150 mg (Alecensa) is a targeted anticancer medicine used to treat ALK-positive non-small cell lung cancer (NSCLC). It works by blocking abnormal ALK proteins that promote cancer cell growth. Alectinib helps slow the progression of the disease, shrink tumours, and may also help control cancer that has spread to the brain.
| Generic name | Alectinib |
| Strength | 150 mg |
| Manufacturer | Roche Products India |
| Package size | 56 Capsules |
| Used for | ALK-positive non-small cell lung cancer (NSCLC) |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries. |
Alectinib is an ALK (anaplastic lymphoma kinase) inhibitor. It works by blocking the abnormal ALK protein that drives the growth and survival of certain lung cancer cells. This action slows or stops cancer cell multiplication and helps control tumour growth.
Dr. Neeru Mehta holds a Doctor of Medicine (MD) degree and has a professional interest in oncology and cancer care. Her interests include cancer treatments, monitoring treatment progress, managing side effects and supportive care.